通化金馬 signed a non-binding agreement to acquire control of a pharmaceutical research company. The counterparty is Bajiayi Pharmaceutical, and the transaction is reportedly expected to include the acquisition of shares.
通化金馬 entered into a non-binding agreement to acquire control of a pharmaceutical research company. The agreement appears to be subject to further negotiations based on mutual agreement between the parties.
The counterparty is Bajiayi Pharmaceutical, and publicly available materials do not provide details such as the specific shareholding ratio or the timing of the acquisition.